Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biopharma Dealmaking Quarterly Statistics, Q2 2013

A look at the financing, M&A, and alliance activity April-June 2013

Executive Summary

Q2 2013 biopharma financing increased 139% to $11 billion over Q1’s $4.6 billion, thanks mostly to two huge transactions by Valeant to fund its $8.7 billion takeover of ophthalmics player Bausch & Lomb, the company’s largest acquisition to date. Options and antibody-drug conjugates featured prominently in the alliances.


Related Content

Amgen’s $125 Per Share Offer For Onyx Reflects Kyprolis Uncertainty
Acquisitive Valeant Sheds Staff As It Closes Bausch & Lomb Deal
GSK Gains T-Cell Vaccine Tech With €250 Million Okairos Acquisition
A Trio Of Strategic VCs Helps To Back Effector Therapeutics With $45 Million
Norway’s Xellia Pharma Acquired By Novo A/S In $700 Million Buyout
Lumena Pharmaceuticals Takes $23M To Fight Rare Liver Disease
Isis Teams Up With Roche In Early-Stage Huntington’s Deal
With Precedents In Place, GenSight Eyes Gene Therapies For Orphan Disorders
Biopharma IPOs Start to Gear Up For 2013 After a Lull
Clavis/Clovis' Pancreatic Cancer Drug Fails Despite Personalized Medicine Approach


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts